Literature DB >> 16624285

The CB2 cannabinoid receptor signals apoptosis via ceramide-dependent activation of the mitochondrial intrinsic pathway.

Blanca Herrera1, Arkaitz Carracedo, María Diez-Zaera, Teresa Gómez del Pulgar, Manuel Guzmán, Guillermo Velasco.   

Abstract

Delta9-tetrahydrocannabinol and other cannabinoids exert pro-apoptotic actions in tumor cells via the CB2 cannabinoid receptor. However, the molecular mechanism involved in this effect has remained elusive. Here we used the human leukemia cell line Jurkat-that expresses CB2 as the unique CB receptor-to investigate this mechanism. Our results show that incubation with the selective CB2 antagonist SR144528 abrogated the pro-apoptotic effect of Delta9-tetrahydrocannabinol. Cannabinoid treatment led to a CB2 receptor-dependent stimulation of ceramide biosynthesis and inhibition of this pathway prevented Delta9-tetrahydrocannabinol-induced mitochondrial hypopolarization and cytochrome c release, indicating that ceramide acts at a pre-mitochondrial level. Inhibition of ceramide synthesis de novo also prevented caspase activation and apoptosis. Caspase 8 activation-an event typically related with the extrinsic apoptotic pathway-was also evident in this model. However, activation of this protease was post-mitochondrial since (i) a pan-caspase inhibitor as well as a selective caspase 8 inhibitor were unable to prevent Delta9-tetrahydrocannabinol-induced loss of mitochondrial-membrane transmembrane potential, and (ii) cannabinoid-induced caspase 8 activation was not observed in Bcl-xL over-expressing cells. In summary, results presented here show that CB2 receptor activation signals apoptosis via a ceramide-dependent stimulation of the mitochondrial intrinsic pathway.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16624285     DOI: 10.1016/j.yexcr.2006.03.009

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  34 in total

Review 1.  CB2: a cannabinoid receptor with an identity crisis.

Authors:  Brady K Atwood; Ken Mackie
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

2.  Cannabinoid (CB2) receptor deficiency reduces the susceptibility of macrophages to oxidized LDL/oxysterol-induced apoptosis.

Authors:  Natalie E Freeman-Anderson; Theresa G Pickle; Courtney D Netherland; Alicia Bales; Nancy E Buckley; Douglas P Thewke
Journal:  J Lipid Res       Date:  2008-07-09       Impact factor: 5.922

Review 3.  Effect of endocannabinoid signalling on cell fate: life, death, differentiation and proliferation of brain cells.

Authors:  Moises Garcia-Arencibia; Eduardo Molina-Holgado; Francisco Molina-Holgado
Journal:  Br J Pharmacol       Date:  2018-06-22       Impact factor: 8.739

Review 4.  CB2 Cannabinoid receptors as a therapeutic target-what does the future hold?

Authors:  Amey Dhopeshwarkar; Ken Mackie
Journal:  Mol Pharmacol       Date:  2014-08-08       Impact factor: 4.436

Review 5.  Cannabinoids, endocannabinoids, and cancer.

Authors:  Daniel J Hermanson; Lawrence J Marnett
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

6.  Potentiation of cannabinoid-induced cytotoxicity in mantle cell lymphoma through modulation of ceramide metabolism.

Authors:  Kristin Gustafsson; Birgitta Sander; Jacek Bielawski; Yusuf A Hannun; Jenny Flygare
Journal:  Mol Cancer Res       Date:  2009-07       Impact factor: 5.852

7.  Functional Selectivity of CB2 Cannabinoid Receptor Ligands at a Canonical and Noncanonical Pathway.

Authors:  Amey Dhopeshwarkar; Ken Mackie
Journal:  J Pharmacol Exp Ther       Date:  2016-05-18       Impact factor: 4.030

Review 8.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

Authors:  R G Pertwee
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

Review 9.  Cannabinoids and gliomas.

Authors:  Guillermo Velasco; Arkaitz Carracedo; Cristina Blázquez; Mar Lorente; Tania Aguado; Amador Haro; Cristina Sánchez; Ismael Galve-Roperh; Manuel Guzmán
Journal:  Mol Neurobiol       Date:  2007-06-28       Impact factor: 5.590

10.  Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: involvement of CB2.

Authors:  N Olea-Herrero; D Vara; S Malagarie-Cazenave; I Díaz-Laviada
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.